Hyris
HYRIS bCUBE is a portable, scalable and connected device for qPCR, available with up to 4 detection channels and IVDR certified.

Helyx Industries is an industrial genetics group whose proprietary PCR-to-NGS molecular biology solutions serve diagnostic laboratories and hospitals.
helyx.bioCrawled Nov 20, 2026
HYRIS bCUBE is a portable, scalable and connected device for qPCR, available with up to 4 detection channels and IVDR certified.
Thanks to customised NGS panels and optimised pipelines, Mytho enables the detection of even low-frequency genomic variants, improving the depth and quality of analysis compared to standard workflows.
Revenue growth results from higher customer satisfaction, increased test volumes, and expanded product offerings.
Mytho uses customized NGS panels and optimized workflows to detect low-frequency genomic variants, improving analysis depth and quality.
Molecular diagnostics is undergoing a radical transformation. From hospital centrality to territorial distribution, from analogue analysis to artificial intelligence, from isolated data to the cloud ecosystem. In this scenario, Helyx Industries | Insights is an editorial platform designed to host visions, trends and analyses on the major changes that are redefining the future of molecular medicine. Not a technical blog, nor a self-referential showcase: a place for strategic reading for those who
The editorial program reflects Helyx Industries’ strategic vision, covering biotech innovation, distributed diagnostics, sustainability, and market trends.
The page shares strategic perspectives, interviews, and analyses from Helyx Industries’ leadership team on decentralized molecular diagnostics.
The page offers strategic insights, interviews, and analyses from Helyx Industries’ leadership team on decentralized molecular diagnostics.
Helyx Industries builds customer-focused solutions through global experience in strategic sectors.
Helyx Industries aims to decentralize diagnostics and health information to create a safer, connected world.
Helyx Industries’ founders have over 20 years of experience developing biomedical products for industry leaders.
Helyx Industries exceeds international standards in its products and operations.
Hyris provides integrated molecular diagnostic solutions for decentralized use, including portable qPCR platforms, software, and reagent production.
Helyx Industries merges Ulisse Biomed’s expertise into three divisions—Hyris, Vytro, and Mytho—offering molecular biology solutions, including PCR, next-generation sequencing, and a proprietary platform.
Helyx Industries receives EU patent approval for its **molecular fingerprinting methods** using polymerase chain reaction (PCR) to detect and genotype DNA targets. The patent covers techniques for identifying genetic sequences through advanced biochemical analysis. The company now holds exclusive rights for this innovation in Europe, expanding its intellectual property portfolio in biotechnology.
Helyx Industries partners with altona Diagnostics Italia to distribute HPV diagnostic solutions and software. The agreement integrates Helyx’s offerings with altona’s real-time PCR molecular diagnostics platform. Both companies specialize in advanced diagnostic tools for healthcare applications.
Helyx Industries reports a consolidated net loss of **€1.4 million** for the first half of 2026, an improvement from the **€2.4 million** loss in the same period of 2025. The company’s non-financial performance (NFP) operations achieve cash positivity, marking a shift in financial trajectory.
Global Corporate Finance LLC has subscribed and paid the second tranche of Helyx Industries Spa’s capital increase. The funding follows an investment agreement signed between the parties on July 31, 2025. This tranche is part of a broader capital raise outlined in the original deal.
Helyx Industries receives a US patent for its molecular fingerprinting technology, enabling DNA target detection and genotyping through PCR. The innovation supports advanced multiplexing for precise genetic analysis. The patent covers key methods for high-throughput molecular diagnostics.
Helyx Industries supplies healthcare screening components to Revvity Italia under the Genoma Puglia Project. The agreement supports Revvity’s Italian operations, which focus on genomic and diagnostic solutions. Helyx’s technology integration aligns with Revvity’s broader healthcare screening initiatives.
Ulisse Biomed rebrands as **Helyx Industries S.p.A.** and reorganizes into three divisions: **Hyris** for integrated qPCR platforms and OEM services, **Vytro** for IVD-certified PCR solutions targeting hospitals and labs, and **Mytho** for customized next-generation sequencing (NGS). The restructuring consolidates the company’s focus on molecular diagnostics and genomic applications. The move follows a strategic shift to streamline operations under a unified brand.